KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Biomarin Pharmaceutical (BMRN) Gross Profit (2017 - 2025)

Historic Gross Profit for Biomarin Pharmaceutical (BMRN) over the last 16 years, with Q3 2025 value amounting to $636.0 million.

  • Biomarin Pharmaceutical's Gross Profit rose 1413.38% to $636.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was $2.5 billion, marking a year-over-year increase of 1590.88%. This contributed to the annual value of $2.3 billion for FY2024, which is 2048.13% up from last year.
  • As of Q3 2025, Biomarin Pharmaceutical's Gross Profit stood at $636.0 million, which was up 1413.38% from $675.3 million recorded in Q2 2025.
  • Over the past 5 years, Biomarin Pharmaceutical's Gross Profit peaked at $675.3 million during Q2 2025, and registered a low of $305.2 million during Q3 2021.
  • Its 5-year average for Gross Profit is $475.5 million, with a median of $460.9 million in 2023.
  • Per our database at Business Quant, Biomarin Pharmaceutical's Gross Profit plummeted by 635.56% in 2021 and then surged by 3002.94% in 2023.
  • Biomarin Pharmaceutical's Gross Profit (Quarter) stood at $330.1 million in 2021, then rose by 18.43% to $390.9 million in 2022, then skyrocketed by 30.03% to $508.3 million in 2023, then increased by 20.24% to $611.2 million in 2024, then rose by 4.07% to $636.0 million in 2025.
  • Its Gross Profit was $636.0 million in Q3 2025, compared to $675.3 million in Q2 2025 and $593.6 million in Q1 2025.